56-Gene Classifier for Immunotherapy Response Prediction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current biomarkers, such as PD-L1 expression, are not reliable for predicting patient responsiveness to immunotherapy in hepatocellular carcinoma (HCC), due to low accuracy and variability in detection methods, leading to inconsistent treatment outcomes.
Innovation Solution
A set of gene expression biomarkers identified through non-negative matrix factorization (NMF) of 956 human HCC samples, which deconvolute the immunological landscape and identify an 'Immune' class with specific biological traits, including high immune cell infiltration and PD-1/PD-L1 expression, providing a 56-gene classifier for predicting immunotherapy responsiveness with high sensitivity and specificity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If PD-L1 expression is used as a biomarker for predicting immunotherapy responsiveness, then treatment guidance is provided, but the detection accuracy is low and results are inconsistent
Solution Approach 1:
The patent transitions from detecting single protein markers (PD-L1) to measuring multiple gene expression parameters simultaneously. The 56-gene signature captures complex immunological states through coordinated expression patterns, fundamentally changing the measurement parameters from simple binary presence/absence to quantitative multi-dimensional gene expression profiles, thereby achieving 97% accuracy in predicting immunotherapy responsiveness
Solution Approach 2:
The patent creates a composite biomarker system by integrating 56 different gene expression measurements into a unified predictive model. Rather than relying on a single marker, the invention combines multiple genetic indicators into a composite signature that collectively predicts treatment response, analogous to creating a composite material with enhanced properties beyond individual components
2Ease of operation
If immunohistochemistry methods are used to detect PD-L1, then treatment guidance is provided, but variability in pathologists' findings leads to inconsistent results
Solution Approach 1:
The patent replaces manual immunohistochemistry staining and visual assessment by pathologists with automated gene expression profiling technology. This substitution eliminates human subjectivity and technical variability inherent in IHC methods, providing objective, reproducible quantitative measurements of gene expression that can be consistently interpreted across different laboratories and clinicians
Solution Approach 2:
The patent introduces an intermediary layer of molecular analysis between tumor detection and treatment decision-making. Instead of directly assessing protein expression through IHC, the invention uses gene expression levels as intermediate indicators that more reliably reflect the functional immune state of the tumor microenvironment, serving as a more consistent mediator for predicting immunotherapy response
3Device complexity
If a single biomarker approach is used, then detection simplicity is maintained, but predictive sensitivity and specificity are insufficient
Solution Approach 1:
The patent segments the complex immunological landscape into 56 distinct gene expression components that can be individually measured and analyzed. By dividing the predictive task across multiple specific gene markers rather than using a single aggregate marker, the system captures nuanced immunological states and achieves superior predictive accuracy while maintaining a structured, analyzable framework
Data Source
AI summary
The present invention relates to methods for detecting, diagnosing, prognosing, monitoring, and treating a patient with hepatocellular carcinoma. In particular, the invention provides diagnostic markers for the detection and treatment of patients who would benefit from immunotherapy, i.e., patient who would be most responsive to immunotherapy.